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ABSTRACT 
A method for treating brain-related chronic pain disorders in 
human Subjects includes assessing the brain function of a 
Subject suffering from chronic pain, diagnosing a chronic 
pain-related abnormal brain condition, and mitigating the 
abnormal brain activity by applying an electrical stimulation 
signal to tissues corresponding to at least one area of abnor 
mal brain activity. 
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BRAIN-RELATED CHRONIC PAIN 
DISORDER TREATMENT METHOD AND 
APPARATUS 
CROSS-REFERENCES TO RELATED 
APPLICATIONS 
0001. This application claims the benefit and is a continu 
ation of U.S. patent application Ser. No. 12/865,286 filed on 
Jul. 29, 2010; which is a continuation of U.S. patent applica 
tion Ser. No. 12/187,375 filed on Aug. 6, 2008; which is a 
continuation-in-part of U.S. patent application Ser. No. 
1 1/490,255 filed on Jul. 21, 2006, now U.S. Pat. No. 7,715, 
910 issued on May 11, 2010; which is a continuation of U.S. 
patent application Ser. No. 10/357,503 filed on Feb. 4, 2003 
which in now abandoned; and claims priority to PCT/ 
US2008/087451 filed on Dec. 18, 2008: PCT/US2008/ 
072395 filed Aug. 6, 2008; and PCT/US2008/072389 filedon 
Aug. 6, 2008; and in turn claims the benefit to U.S. Provi 
sional Application Ser. No. 61/032,241 filedon Feb. 28, 2008: 
U.S. Provisional Application Ser. No. 61/024,641 filed on 
Jan. 30, 2008; U.S. Provisional Application Ser. No. 61/014, 
917 filed on Dec. 19, 2007; U.S. Provisional Application Ser. 
No. 60/963.486 filed on Aug. 6, 2007 and U.S. Provisional 
Application Ser. No. 60/353,234 filed on Feb. 4, 2002; all of 
which are incorporated herein by reference in their entireties. 
TECHNICAL FIELD 
0002 This invention relates generally to a method and 
apparatus for treating brain-related chronic pain disorders in 
human Subjects. 
BACKGROUND OF THE INVENTION 
0003. Few methods are known in the prior art for treating 
brain-related chronic pain disorders such as fibromyalgia. 
U.S. Pat. No. 7,146,205 issued 5 Dec. 2006 to Holman, dis 
closes a fibromyalgia treatment method including the use of 
inhibitors of sympathetic nervous system activities. U.S. Pat. 
No. 5,990,162, issued 23 Nov. 1999 to Scharf, discloses a 
fibromyalgia treatment method that involves the use of 
butyrate derivatives. U.S. Pat. No. 5,378,686, issued 3 Jan. 
1995 to Bennett, discloses a fibromyalgia treatment involving 
the use of Supplemental growth hormone. In each of these 
documents the inventors teach methods that likely address 
central nervous system and neurotransmitter outcomes that 
result from the fundamental role of brain function in the 
pathology of fibromyalgia. However, the methods disclosed 
in these patents are unable to treat the fundamental brain 
function abnormality related to fibromyalgia that causes 
chronic pain. 
0004. In addition, United States Patent Application Publi 
cation No. 20070191905 published 16 Aug. 2007; Nos. 
20070179563 and 20070179564 published 2 Aug. 2007, No. 
20070156182 published 5 Jul. 2007, No. 20070106339 pub 
lished 10 May 2007, and No. 20070106342 published 10 May 
2007, disclose the use of electrical stimulation to treat 
hypotension, vision disorders, dysphagia, and pain, respec 
tively. However, none of the methods disclosed in these pub 
lications are able to treat a brain function abnormality that is 
at least partially responsible for causing chronic pain. 
0005 What is needed is a method and apparatus for treat 
ing brain-related chronic pain disorders in human Subjects 
that can treat a fundamental brain function abnormality asso 
ciated with chronic pain. 
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SUMMARY OF THE INVENTION 
0006. A method for treating a brain-related chronic pain 
disorder in a human Subject is provided. According to this 
method one can treat a brain-related chronic pain disorder in 
a human Subject by assessing the brain function of a subject 
Suffering from chronic pain, diagnosing a chronic pain-re 
lated abnormal brain condition, and mitigating the abnormal 
brain activity by applying an electrical stimulation signal to 
tissues corresponding to the at least one area of abnormal 
brain activity. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0007. These and other features and advantages of the 
invention will become apparent to those skilled in the art in 
connection with the following detailed description, drawings, 
photographs, and appendices, in which: 
0008 FIG. 1A is a flow chart depicting a method per 
formed according to the invention; 
0009 FIG. 1B is a continuation of the flow chart of FIG. 
fio FIG. 1C is a continuation of the flow chart of FIG. 
fill FIG. 1D is a continuation of the flow chart of FIG. 
Foia FIG. 1E is a continuation of the flow chart of FIG. 
Fis FIG. 2 is a schematic diagram showing an apparatus 
for treating a brain-related chronic pain disorder according to 
the invention; 
0014 FIG. 3 is a schematic diagram showing a signal 
generating circuit of the apparatus of FIG. 2; 
0015 FIG. 4 is a schematic diagram showing an embodi 
ment of an apparatus for treating a brain-related chronic pain 
disorder according to the invention and showing atherapy cap 
of the apparatus and a subjects head cut-away to reveal 
electrical stimulation signal paths relative to target areas of 
the subject’s brain tissue: 
0016 FIG. 5 is a schematic diagram showing an embodi 
ment of an apparatus for treating a brain-related chronic pain 
disorder according to the invention and showing atherapy cap 
of the apparatus cut-away to reveal an RFID chip carried by 
the cap; and 
0017 FIG. 6 is a schematic diagram showing an embodi 
ment of an apparatus for treating a brain-related chronic pain 
disorder according to the invention and showing atherapy cap 
of the apparatus cut-away to reveal a programmable memory 
circuit carried by the cap. 
DETAILED DESCRIPTION OF INVENTION 
EMBODIMENT(S) 
0018. A method is provided for treating a brain-related 
chronic pain disorder. The method includes assessing the 
brain function of a Subject Suffering from chronic pain, diag 
nosing a chronic pain-related abnormal brain condition, 
locating at least one area of abnormalbrainactivity associated 
with the abnormal brain condition and mitigating the abnor 
mal brain activity by applying a neuromodulation signal to 
tissues corresponding to the at least one area of abnormal 
brain activity. Alternatively, the neuromodulation signal com 
prises waveforms designed to minimize tissue impedance 
while effecting noninvasive neuromodulation. Treatment 
effect is realized when abnormal brain function has been 
improved or corrected. 
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0019. A physical assessment may first be performed of a 
human Subject presenting with a complaint of symptoms 
characteristic of a chronic pain condition Such as fibromyal 
gia. The physical assessment may include, among other 
things, a determination of chronic widespread pain, sleep 
difficulty, fatigue, morning stiffness of the muscles and joints, 
cognitive difficulty, and other symptoms associated with the 
condition. The physical assessment may also include tests 
performed to exclude various non-fibromyalgia conditions as 
the cause of the symptoms. Such further testing may include 
palpation of 18 tender points in the manner prescribed by the 
American College of Rheumatology, with Such palpation 
being performed to determine whether the subject has an 
abnormal sensitivity to pain. 
0020. In the absence of an alternate, non-fibromyalgia 
diagnosis, an electroencephalogram (EEG) test may be per 
formed in addition to the physical assessment, whereby the 
EEG test is performed utilizing methods and apparatus well 
known in the art. Specifically, the Subject may be made com 
fortable by, for example, being seated, or reclined. Prepara 
tion of the scalp in accordance with commonly followed 
procedures for performing a clinical EEG may be done by a 
person of sufficient competence. EEG electrodes may then be 
adapted to be worn on the Scalp, preferably in Scalp locations 
identified as the “International 10-20 standard sites, using 
common methods of affixing the electrodes Such that they rest 
on or otherwise contact tissues. 
0021 While any number of electrodes may be used, a 
preferred number is either 19 or 24, in accordance with the 
number of electrode sites used to construct various indepen 
dent databases utilized to represent the EEG of a healthy 
normal population, and to facilitate quantitative assessment 
(qEEG) of the subjects EEG. Methods involving qEEG 
include a number of mathematical analyses utilized to make 
statistical comparisons between the Subject’s qEEG and a 
database of qEEGs of either healthy normal individuals’ brain 
functions or the brain functions of individuals suffering from 
chronic pain related brain function conditions. 
0022 Records of the subject's EEG from each electrode 
site may then be acquired under the conditions of both their 
eyes being closed and their eyes being open, with each con 
dition producing a separate data record. In other words, an 
“eyes open' EEG record may be obtained, which includes 
EEG data obtained from each electrode site while the sub 
ject’s eyes are open and an “eyes closed EEG record may be 
obtained, which includes EEG data obtained from each elec 
trode site while the subject’s eyes are closed. Preferably, a 
minimum of five minutes of EEG data may be obtained from 
each electrode site for each "eyes open EEG record and a 
minimum of five minutes of EEG data may be obtained from 
each electrode site for each "eyes closed EEG record to 
assure that enough EEG data is recorded to produce statisti 
cally significant samples from each electrode site, both with 
the subject’s eyes open and with the subject’s eyes closed. 
This is further described below. 
0023 Preferably, an additional test may be performed in 
which at least one additional EEG record is made that 
includes EEG data obtained at each electrode site while the 
subject’s eyes are closed. In this test, henceforth referred to as 
a “tender point palpation (TPP) test”, a number of tender 
points on the Subject’s body, preferably ranging between one 
and 18, are identified and serially palpated with an algometer. 
Preferably, four tender points may be chosen, and, preferably, 
those four points include tender points adjacent the right and 
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left lateral epicondyle of the arms approximately two centi 
meters distal of the elbows, and tender points adjacent the 
right and left costochondral junctions of the second rib. 
0024. The TPP test may be executed by acquiring an EEG 
record (“TPP” EEG record) including EEG data obtained 
from the electrode sites for a first tender point by first com 
mencing the acquisition of EEG data and then, a short period 
of time later, commencing palpation of the first tender point. 
Preferably, the period of time between the commencement of 
data acquisition and the commencement of palpation of the 
first tender point may be between one and 300 seconds. Pal 
pation of the first tender point may be accomplished by press 
ing on the tender point preferably pressing or palpating 
through the use of an algometer, and preferably at a rate of 
approximately one kilogram per centimeter squared per sec 
ond, until the Subject reports a painful sensation or until 
reaching a pressure of 4 kilograms per centimeter squared— 
whichever occurs first. Preferably, palpation pressure may be 
removed as soon as the Subject reports a painful sensation. A 
record is made of the amount of the pressure being applied at 
the moment the Subject reports a painful sensation. 
(0025. Further according to the TPP test method, the 
recording of the “eyes closed EEG may continue for a period 
of time after release of palpation pressure, preferably between 
1 and 300 seconds, and most preferably, for at least 60 sec 
onds. Following this period, a second and Subsequent tender 
point may be serially palpated with an algometer in the same 
manner as described for the first, with “TPP” EEG records 
being recorded for each by recording the “eyes closed EEG 
for each site in the manner described with regard to obtaining 
the “TPP” EEG record for the first site. This process may be 
repeated for each chosen tender point. Accordingly, the 
resulting EEG data record includes the “TPP” EEG records 
acquired for each chosen tender point. 
(0026. The “TPP” EEG records may be acquired for a 
period of time that is sufficient to extract from each “TPP 
EEG record a minimum of 60 seconds of “clean EEG data, 
that is, data free of extraneous electrical noise Such as that 
from electromyographic movement. Preferably, all EEG 
records (“eyes open EEG records, “eyes closed EEG 
records, and “TPP” EEG records) may be individually edited 
to provide from each EEG record a minimum of 60 seconds of 
clean EEG. Preferably, the clean data is obtained to present a 
high degree of statistical consistency. Such measures as 
“Split-Half reliability, which is the ratio of variance between 
the even and odd seconds of the time series of selected clean 
EEG; and “Test Re-test” reliability, which is the ratio of 
variance between the first half and the second half of the 
selected clean EEG segments may be used. Preferably, clean 
EEG data is obtained such that measures of these ratios are a 
minimum of 0.95 and 0.90 respectively, which is consistent 
with levels of reliability commonly published in EEG litera 
ture. 
(0027. With regard to the TPP test method, clean data 
includes only that EEG data acquired after palpation of a 
tender point, and does not include any EEG data acquired 
during the palpation of a tender point. In addition, to assess 
the stability of a “TPP” EEG record, EEG data acquired 
before palpation of a tenderpoint may be removed, edited and 
statistically compared to like data in the “eyes closed EEG 
record obtained from the “eyes closed EEG test. Stability of 
the “eyes closed” and “TPP” EEG records is indicated by a 
finding that there is no statistically significant difference 
between the “eyes closed EEG record and the pre-palpation 
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portion of the “TPP EEG record. A contrary finding indi 
cates instability and a need to repeat the EEG tests. 
0028. Further to the method, and in the preferred embodi 
ment, clean “eyes open”, “eyes closed”, and “PPT EEG 
records may be then mathematically analyzed for various 
time domain and frequency domain parameters of their 
respective electrical signals. These analyses may include, but 
are not limited to Voltage analysis, current analysis, Voltage 
and current analysis, frequency spectrum analysis using Fast 
Fourier transform analysis, frequency spectrum analysis 
using a wavelet analysis method, frequency spectrum analy 
sis using absolute power analysis method, frequency spec 
trum analysis using relative power analysis method, fre 
quency spectrum analysis using phase analysis method, 
frequency spectrum analysis using coherence analysis 
method, frequency spectrum analysis using amplitude sym 
(2t Criterion for Making a Diagnosis of Fibromyalgia 
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cant'. However, inclinical application statistically significant 
differences may be declared with p-values at the 0.1 level or 
less. 
0031. Further EEG abnormalities consistent with those 
observed in a sample population offibromyalgia patients, and 
drawn particularly to the TPP test method, may include but 
are not limited to a finding of (1) a statistically significant 
increase in EEG absolute power, particularly in the alpha and 
beta segments, in the parietal, occipital, and temporal areas of 
the brain as compared to the “eyes closed EEG record ("eyes 
closed EEG findings without tender point palpation) for the 
same Subject; or (2) a statistically significant increase in 
coherence in the alpha or beta segment of EEG. The following 
are the results of tests of the predictive value of TPP sensitiv 
ity analysis, obtained when TPP testing was utilized on 19 
fibromyalgia patients and compared to TPP testing done on 
nine healthy normal controls: 
Positive 
(2nsitivity (2)ecificity (2)ictive Value 
(2)crease in alpha EEG of at least 20% in at least one 63% 89% 92% 
occipital or parietal site 
(2ncrease in alpha EEG of at least 20% in at least one 84% 78% 89% 
temporal site 
(2)otal regions of increase in alpha EEG of at least 20% 74% 100% 100% 
are greater than two 
(2EEG coherence increases by at least 20% in at least 84% 88% 94% 
30 out of 171 possible site combinations 
(2)ast two (2) positive findings occur in any of the four 90% 100% 100% 
previous tests 
*Based on comparison of TPPEEG data against eyes closed EEG data 
(2) indicates text missing or illegible when filed 
metry analysis method, and localization of electrical activity 
in the brain using inverse EEG computation analysis. 
0029 Findings from the aforementioned analyses may 
then be statistically compared to the same parameters deter 
mined from “eyes open”, “eyes closed”, and “PPT EEG 
records taken from an age and gender matched database of 
healthy normal individuals. Such statistical analyses may 
include, but are not limited to deviations from a standard 
normal distribution. Findings of Statistically significant 
abnormal deviation, or lack thereof, may then be presented in 
a graphical or numerical format for analysis by a competent 
health care professional or person of similar expertise. 
0030 EEG abnormalities consistent with those observed 
in a sample population of fibromyalgia patients may include, 
but are not limited to one or more of the following: (1) an 
overall reduction in EEG power across all spectra in either of 
the “eyes open' or “eyes closed’ conditions; (2) statistically 
significant low EEG power levels in frontal or temporal 
regions of any of the delta (1-3.5 hertz), theta (4-7.5 hertz) or 
alpha (8-12 hertz) frequency segments of EEG for the “eyes 
closed’ condition; (3) statistically significant low coherence 
among the frontal EEG sites for the delta or theta EEG seg 
ments in either of the “eyes closed’ or “eyes open condi 
tions; (4) statistically significant high relative beta (12.5-25 
hertz) absolute power in the parietal region of the brain for 
either of the “eyes closed’ or “eyes open conditions. The 
magnitude of statistical variation considered statistically 
“significant may vary depending on the application. For 
example, in research, a difference between a sample and a 
population measure generally has to have a p-value of 0.01 or 
less for the difference to be considered statistically “signifi 
0032. A diagnosis of fibromyalgia may be made when 
physical assessment findings that Support a diagnosis of 
fibromyalgia are augmented by making a quantitative assess 
ment including but not necessarily limited to a statistical 
comparison between the subject’s qBEG and a database of 
quantitative assessments of either healthy normal individuals 
or individuals suffering from a chronic pain related abnormal 
brain function condition Such as fibromyalgia. In the pre 
ferred embodiment, statistical findings that Support a diagno 
sis of fibromyalgia may include, but are not necessarily lim 
ited to, (1) an abnormal finding resulting from the TPP test, 
preferably a finding of a statistically significant increase in 
EEG absolute power, and particularly in the alpha and beta 
segments, in the parietal, occipital, and temporal areas of the 
brain as compared to the “eyes closed findings without ten 
derpoint palpation for the same subject; and preferably (2) an 
abnormal finding resulting from the “eyes closed EEG test, 
preferably statistically significant low EEG power levels in 
frontal or temporal regions of any of the delta, theta or alpha 
frequency segments of EEG for the “eyes closed’ condition, 
and most preferably with an additional finding of statistically 
significant low coherence among the frontal EEG sites for the 
delta or theta EEG segments. Alternately, fibromyalgia may 
be diagnosed by statistically comparing a Subjects one or 
more qBEG parameters to like qEEG parameters obtained 
from at least one healthy normal individual; then comparing 
the one or more deviations to deviations detected in a sample 
population of known fibromyalgia patients. 
0033 Clean EEG records from a subject may be math 
ematically analyzed for various time domain and frequency 
domain parameters of their electrical signals, consistent with 
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analysis techniques already described, and then findings from 
these mathematical analyses may be statistically compared to 
like parameters taken from an age and gender matched data 
base of healthy normal individuals or individuals known to 
have fibromyalgia. The statistical comparisons may include, 
but are not limited to deviations from a standard normal 
distribution of like EEG measures associated with members 
of a database of healthy normal individuals or individuals 
known to have fibromyalgia. The results of those compari 
Sons may then be presented in a graphical or numerical format 
for analysis by a competent health care professional or person 
of similar expertise for the existence of statistically signifi 
cant abnormal deviations, or the lack thereof. A finding in 
Support of a fibromyalgia diagnosis would be supported if 
there is an absence of any significant deviation between mea 
sures from a subjects clean EEG and those from a database 
comprising individuals known to have fibromyalgia. 
0034 Analyses of clean EEG from a subject may be sta 
tistically correlated to measures of symptom severity. As 
previously described, analysis findings may be mathemati 
cally analyzed for various time domain and frequency domain 
parameters of electrical signals. A number of measures of the 
magnitude of deviation from standard normal distributions of 
either healthy normal EEG or known fibromyalgia patient 
EEG can be determined. The magnitudes may be presumed to 
be related to the severity of the condition and may be statis 
tically correlated to such symptom measures that may 
include, but are not limited to, tender point pain pressure 
thresholds as determined by an algometer, and various other 
indices of pain derived from the algometry measures (e.g. the 
Sum of all 18 tender point pain tolerance measures, the aver 
age of all 18 tender point pain tolerance measures, etc.). Such 
analysis has utility in both predicting symptom severity in 
individuals with fibromyalgia, and in determining the effect 
of therapeutic intervention to corrector manage symptoms of 
fibromyalgia. 
0035 EEG analyses may also be used for determining the 
location of abnormal brain activity and further for determin 
ing points for application of neuromodulation. 
0036 Treatment may include the application of a nonin 
vasive neuromodulation signal in a manner designed to cor 
rect abnormalbrain function identified inaccordance with the 
aforementioned EEG analyses. Suitable noninvasive neuro 
modulation techniques are disclosed in applicant's U.S. 
patent application Ser. No. 1 1/490,255 and applicant’s Inter 
national Patent Application Ser. No. PCT/US2008/72395, 
which are incorporated herein by reference. The noninvasive 
neuromodulation signal may comprise those waveforms 
designed to minimize tissue impedance. Such as an “ampli 
tude modulated pulse width modulated’ (AMPWM) signal. 
An AMPWM signal utilizes a high frequency carrier signal 
that is amplitude modulated by a low frequency neuromodu 
lation signal. The carrier signal is of Sufficiently high fre 
quency so as to be less attenuated by the impedance of tissues 
due to their capacitive reactance. The frequencies used in the 
neuromodulation signal are lower than the frequency of the 
carrier signal, and are chosen to provide therapeutic benefit. 
By using the neuromodulation signal to amplitude modulate 
the carrier signal, and Subsequently applying the combined 
signal to tissues, the neuromodulation signal is less attenuated 
by the impedance of the tissue permitting greater penetration 
of electrical current and field. The carrier signal is further 
pulse width modulated in an AMPWM signal to control the 
time averaged current, and hence the power of the signal 
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delivered to the tissues. An apparatus for generating and 
delivering an AMPWM signal includes any number of elec 
tric signal generating devices capable of generating and alter 
ing the parameter aspects of an AMPWM signal. Various 
forms of an AMPWM signal and apparatus for generating an 
AMPWM signal are disclosed in the applicant's U.S. appli 
cation Ser. No. 1 1/490,255 and applicant’s International 
Patent Application Ser. No. PCT/US08/72395. Reports on the 
results of a double-blind, placebo-controlled study of the 
efficacy of this treatment are summarized below: 
0037. Thirty-nine (39) active treatment (AT) fibromy 
algia patients and 38 comparable placebo control 
patients completed non-invasive neuromodulation treat 
ment, applied twice a week for 11 weeks. The placebo 
condition (PL) was created by not delivering the non 
invasive neuromodulation signal. Both number of tender 
point (defined by the American College of Rheumatol 
ogy) and total pain score were evaluated at baseline and 
end of treatment. Subjects also completed health impact 
questionnaires (Fibromyalgia Impact Questionnaire 
FIQ, Symptom CheckList-90SCL-90), Beck Depres 
sion Inventory BDI. and sleep quality) at baseline and 
end of treatment period, and FIQS in long-term follow 
up. Primary outcome measures were changes in the 
number of tender points (TePs) and level of TeP pain, 
secondary measures were changes in the questionnaire 
responses. 
0.038 Analysis of results showed AT patients improved 
in number of positive TePs, mean 17.4 pre-treatment to 
9.9 post-treatment (P<0.001). The between group 
change was significantly improved (PL -0.2 versus AT 
–7.4, P-0.001). Sixty-two percent (62%) of the AT 
group no longer met the tender point criteria for FM 
classification following treatment. Similarly, the tender 
point score (TPS) for the AT group improved from 36.7 
to 56.4 (P<0.001) whereas the control group got slightly 
worse, 38.9 to 35.8. The between group change was also 
significantly improved (PL -3.2 versus AT +19.6, P-0. 
001). The total FIQ score in the AT group improved from 
65.1 to 46.0 (P<0.001). In other measures, the AT group 
reported 61.8% improvement in sleep quality (P<0. 
001). Long term follow-up FIQ analysis was done at an 
average of 16.8 months since discontinuation of treat 
ment (range 12-28 months). There was a continuing long 
term improvement over baseline values (P<0.001). 
There were no significant side effects. 
0039 Mitigation of abnormal activity is accomplished by 
generating and applying to the Subject an electrical stimula 
tion signal having at least one parameter configured to modu 
late at least one abnormal aspect of the subject's EEG, which 
corresponds to at least one statistically significant difference 
found in the statistical comparison of qEEGs. Such abnormal 
aspects of the subject's EEG may include, but are not limited 
to, abnormally high or low amplitudes, abnormal amplitudes 
in specific frequencies or frequency segments, abnormal 
spectral power, abnormal relative power, amplitude asymme 
try, and abnormally high or low coherence. The application of 
said electrical stimulation signal, preferably an AMPWM 
noninvasive neuromodulation signal, may comprise a first 
step of choosing neuromodulation signal parameters 
intended to correct abnormal brain function identified in 
accordance with the aforementioned EEG analyses. These 
parameters may include, but are not limited to, a choice of the 
carrier signal frequency, neuromodulation signal frequency, 
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amplitude, waveform, duty cycle, application times, and 
phase. The step of choosing neuromodulation signal param 
eters may include identifying a particular signal parameter, 
Such as a frequency from a patient's EEG, that is statistically 
different than normal, e.g., an EEG frequency that is lower 
than normal at a particular location. The chosen neuromodu 
lation signal parameters may thus, for example, include a 
frequency generally equal to that of the abnormally low mea 
Sured EEG frequency. The step of choosing neuromodulation 
signal parameters may alternatively or additionally include 
identifying an area of the brain where the spectral amplitude 
of an EEG frequency measure is found to be statistically 
different than normal. This step may further include identi 
fying the direction and magnitude of said spectral amplitude 
deviation from normal for said statistically different than 
normal EEG frequency measure. The identifying step may 
yet further include choosing signal parameters that include 
frequencies ranging between the frequency of the statistically 
different than normal measure (F1) and a frequency that is (a) 
within an approximate range of from 20 Hertz greater than F1 
to F1 for the case in which the direction of deviation for F1 is 
less than normal; or (b) within an approximate range of from 
20 Hertz less than F1 to F1 for the case in which the direction 
of deviation for F1 is greater than normal. The identifying 
step may further include choosing signal amplitudes and 
application times that are proportional to the magnitude of 
deviation from normal for said statistically different than 
normal EEG frequency measure. The identifying step may 
further include choosing signal duty cycle so as to provide a 
signal that cannot be felt by a person when applied. The 
identifying step may further include choosing a signal wave 
form that encompasses at least one of the frequencies in the 
range of F1 plus or minus 20 Hertz. The identifying step may 
also include applying at least two neuromodulation signals to 
different areas of the brain, and applying a phase shift 
between the at least two signals where the phase shift may 
range between Zero and 180 degrees. 
0040. The application of a noninvasive neuromodulation 
signal may further comprise the step of choosing neuromodu 
lation signal application location to provide for application of 
neuromodulation to tissues corresponding to one or more of 
the spatial location(s) of abnormal brain function identified 
by the aforementioned analyses. Signal application may fur 
ther include the use of electrodes to create a signal path 
between an electrical stimulation signal source Such as an 
apparatus for generating an AMPWM signal and a stimulat 
ing electrode positioned proximate to brain tissues in at least 
one area of abnormal brain activity, either invasively or non 
invasively. 
0041) Delivery of the neuromodulation signal may be 
accomplished by utilizing an electrode set comprising inva 
sive stimulating electrodes positioned on or in near proximity 
to brain tissues exhibiting abnormal function, i.e., within 
approximately 20 mm. The electrode set may further com 
prise an invasive ground electrode positioned Such that a 
vector path between stimulating electrodes and a ground elec 
trode passes through tissues to be stimulated. 
0042. Delivery of the neuromodulation signal may be 
accomplished by utilizing an electrode set comprising one or 
more non-invasive stimulating electrodes adapted to be worn 
by a subject such that the stimulating electrodes rest on the 
Scalp in proximity to brain tissues exhibiting abnormal func 
tion. The electrode set may further comprise a non-invasive 
ground electrode adapted to be worn by a subject such that the 
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non-invasive ground electrode rests on the scalp in proximity 
to brain tissues exhibiting abnormalfunction; positioned Such 
that a vector path between non-invasive stimulating elec 
trodes and a non-invasive ground electrode passes through or 
in near proximity to tissues to be stimulated. 
0043. Delivery of the neuromodulation signal may be 
accomplished by utilizing an electrode set comprising one or 
more non-invasive stimulating electrodes adapted to be worn 
by a subject such that the stimulating electrodes rest on the 
skin posterior to the cervical vertebrae and in proximity to the 
vagus nerve. The electrode set may further comprise a non 
invasive ground electrode adapted to be worn by a subject 
Such that the non-invasive ground electrode rests on the scalp 
in proximity to brain tissues exhibiting abnormal function; 
positioned such that a vector path between non-invasive 
stimulating electrodes and a non-invasive ground electrode 
passes through or in near proximity to tissues to be stimu 
lated. 
0044) The period of time over which therapeutic interven 
tion takes place may comprise repeated application of a neu 
romodulation signal for finite duration, with rest time taking 
place between applications, and total number of applications 
comprising a finite number. The finite duration may be 
between one second and 60 minutes; the rest time may be 
between one minute and seven days; and the total number of 
applications may be between one application and 300 appli 
cations. The number of applications may be proportional to 
either the extent of abnormal function and/or the time that the 
abnormal function has been present 
0045. The method of generating described neuromodula 
tion signals may include the use of an apparatus such as that 
disclosed in the applicant's U.S. patent application Ser. No. 
1 1/490.255, which is assigned to the assignee of the present 
application and incorporated herein by reference. 
0046. The method may include the steps of repeating 
quantitative assessments such as EEG testing, TPP testing 
and statistical analysis on a subject, as described herein, fol 
lowing a period of therapeutic intervention on said Subject. 
The method may further comprise statistical comparison of 
parameters of the repeated Statistical analysis to like param 
eters of the statistical analysis of the subject done before the 
previous therapeutic intervention was started. Such compari 
son might include, but is not limited to, paired t-testing sta 
tistics, correlation analysis of changes in Symptom severity, 
and Subsequent comparison to a database of age and gender 
matched healthy normal individuals or individuals suffering 
from a brain related chronic pain condition Such as fibromy 
algia. These comparisons may be used to assess the effective 
ness of the therapeutic intervention, in particular noninvasive 
neuromodulation, or to determine if an alternate intervention 
is indicated in the absence of treatment effect from a current 
therapeutic intervention. The comparisons could also be used 
to determine if further therapeutic intervention is indicated in 
the absence of any abnormal findings. The comparisons may 
further be used to modify neuromodulation signal parameters 
in accordance with the findings of the repeated quantitative 
assessment step. 
0047. With specific reference to the TPP test, repeat test 
ing may include the application of tender point pressure 
using, e.g., an algometer, only to the levels required to cause 
a painful response recorded in the same testing performed 
before therapeutic intervention. 
0048. Further according to the method, EEG data may be 
acquired at a first location (e.g. a clinical location) and the 
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acquired EEG data transferred via electronic means to 
another location (e.g. a central analysis location) for the 
herein described analysis and statistical comparisons to be 
accomplished. The electronic means of data transfer may 
include, but isn't limited to means of data transfer across a 
local area network and/or the Internet. Consequently, analysis 
and Statistical findings may then be transferred from a central 
analysis location to a clinical location, where they may be 
used in various ways by a physician or similarly qualified 
health care professional for the determination of parameters 
of a neuromodulation signal used for therapeutic intervention 
and treatment of fibromyalgia. 
0049 Further according to the method, EEG data may be 
acquired at a first location (e.g. a clinical location) and the 
acquired EEG data transferred via electronic means to 
another location (e.g. a central analysis location) for a pur 
pose such as increasing the size of various databases of indi 
viduals known to be suffering from fibromyalgia, individuals 
known to be suffering from a chronic pain condition that is not 
fibromyalgia, and healthy normal individuals. 
0050. Further according to the method, neuromodulation 
signal parameters may be determined at a central analysis 
location and Subsequently transferred as data via electronic 
means to an apparatus at another location (e.g. a clinical 
location) provided for delivery of a neuromodulation signal 
used for therapeutic intervention and treatment of fibromyal 
gia. The electronic means of data transfer may include, but 
isn't limited to, means of data transfer across a local area 
network and/or the Internet. 
0051. The steps of application of the neuromodulation 
signal and repeat measurements and analyses of a subjects 
EEG may be continued until abnormal brain function, as 
determined by, for example, EEG analysis, is modulated and/ 
or mitigation or resolution of symptoms of the chronic pain 
condition (such as fibromyalgia) are achieved. 
0052 Alternatively, non-EEG methods of assessing brain 
function may be utilized to quantify and locate abnormal 
brain function. Such methods include, but are not limited to 
positron-emission tomography (PET) scans, magnetic reso 
nance imaging (MRI) testing and single photon emission 
computed tomography (SPECT) scans. 
0053 Alternatively, EEG data may be collected during a 
therapeutic intervention that includes application of an elec 
trical stimulation signal Such as a neuromodulation signal, 
and that EEG data may be analyzed by real-time computa 
tional algorithms such as Fast Fourier Transforms (FFT) to 
determine various statistics associated with EEG, including 
but not limited to spectral amplitudes of frequencies compris 
ing said EEG. The statistics may be used to modify param 
eters of a neuromodulation signal for the purposes of opti 
mizing therapeutic benefit. In a preferred embodiment, EEG 
data collected during a therapeutic neuromodulation signal 
application is analyzed for spectral components using an FFT 
algorithm. A comparison between the frequency of a stimu 
lation signal and the highest spectral amplitude of measured 
EEG signal is made. If said comparison finds these frequen 
cies to be the same, then a corresponding modification to the 
neuromodulation signals frequency would be made. 
0054 As shown in FIG. 2, the abnormal brain function 
diagnostic and treatment apparatus 100 may include a com 
puter 101 interfaced to a signal generation and interface mod 
ule 121 utilizing any number of methods known in the art such 
as the use of a computer interface cable 102. Any power 
source 103 known in the art to sufficiently provide power to 
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computers and electronic devices may be utilized and exter 
nally interfaced with power wires 104. The signal generation 
and interface module 121 may include a microcontroller 106 
electronically coupled to a signal generator circuit 107, to an 
EEG acquisition circuit 108 and to any number of device 
interface circuits 109. All external interfaces may utilize con 
nectors 105 commonly known in the art. All electrical and 
electronic coupling methods may utilize conductors 112 
known in the art. 
0055. In practice, the computer 101 may be configured to 
communicate via interface 102 to the microcontroller 106 for 
various purposes including the transfer of AMPWM signal 
parameters and the receipt of EEG data. The computer 101 
may include a user interface that allows an operator to moni 
tor and/or influence operation of the diagnostic and treatment 
apparatus 100. 
0056. A neuromodulation signal such as an AMPWM sig 
nal may be generated in the signal generator circuit 107 and 
delivered to a stimulation signal interface 110 that includes 
connectors 105. As shown in FIG. 3, the signal generator 
circuit 107 may comprise a biopotential amplifier 114 that 
measures EEG signals and may be operatively coupled to any 
number of filter 115 circuits configured to reduce extraneous 
electrical noise in an EEG signal. The biopotential amplifier 
114 may be further operatively coupled to an isolation ampli 
fier 116 for human subject protection, and to a microcontrol 
ler 106 through an analog-to-digital interface 117. In opera 
tion, EEG may be acquired through a stimulation signal 
interface 110 comprising electrical conductors 5 interfaced at 
connectors 105. The acquired EEG may be conducted to a 
biopotential amplifier 114, filter circuits 115, isolation ampli 
fier 116 and to a microcontroller 106 for use such as, but not 
limited to, in software executed by an interfaced computer 
101 for generating and delivering an AMPWM signal. The 
signal generator circuit 107 may further comprise an isolated 
power supply 118 configured to provide circuit power and 
provide human Subject protection, a Switching transistor 119 
that has base connection to a digital-to-analog interface 121 
on a microcontroller 106, and an inductor 120 configured and 
positioned to induce an electrical stimulation signal Such as 
an AMPWM signal into a conductor 112 leading to a connec 
tor 105 in a stimulation signal interface 110. In operation, the 
microcontroller 106 may generate a stimulation signal and 
conduct that signal via a digital-to-analog interface 121 to the 
base of the switching transistor 119. Electrical power from an 
isolated power supply 118 may then switched on and off 
through the Switching transistor 119 creating an amplified 
stimulation signal in accordance with the stimulation signal 
waveform generated by the microcontroller 106. The ampli 
fied stimulation signal may be further conducted to an induc 
tor 120, and further induced into a conductor 112 creating a 
therapy stimulation signal in the conductor 112. The therapy 
stimulation signal may then be delivered to a human Subject 
via the conductor 112 to a stimulation signal interface 110 
comprising electrical conductors 5 interfaced at connectors 
105. In other words, the neuromodulation signal may be 
applied using an apparatus comprising a microcontroller 106 
configured to generate signal waveforms and coupled to a 
signal generator circuit 107 configured to transform the signal 
waveforms into desired AMPWM neuromodulation signals. 
The signal generator circuit 107 may comprise circuit ele 
ments such as a biopotential amplifier 114 configured to 
measure EEG signals, a filter circuit 115 configured to reduce 
electrical noise in EEG signals, an isolation amplifier 116 
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configured to protect human Subjects, an analog-to-digital 
interface 117 configured to convert analog EEG signals to 
digital signals, an isolated power Supply 118 configured to 
provide circuit power and human Subject protection, a Switch 
ing transistor 119 configured to generate an amplified stimu 
lation signal by Switching on and off electrical power from the 
isolated power Supply in response to stimulation signals 
received at a base of the switching transistor from the micro 
controller, and an inductor 120 configured to induce an elec 
trical stimulation signal into a conductor 112. Additional 
forms of an AMPWM signal and apparatus for generating an 
AMPWM signal are disclosed in the applicant's U.S. patent 
application Ser. No. 1 1/490.255, which is incorporated herein 
by reference in its entirety. 
0057. As shown in FIG.4, the apparatus 100 may include 
a cap 3 configured to be worn on a subjects head in a prede 
termined orientation. At least two electrodes 1, 2, which may 
be non-invasive type electrodes, may be carried by the cap. 
One of the electrodes 1 may be configured to act as a stimu 
lating electrode 1 for delivering a neuromodulation signal to 
the subject's head 4, and the other of the electrodes 2 may be 
configured to act as a ground electrode and to receive neuro 
modulation signals transmitted by the signal delivery elec 
trode 1. The cap 3 may be of any suitable configuration to 
include a skull-cap configuration as shown in the drawings, or 
may simply comprise flexible bands. In any case, the cap 3 is 
adapted to carry the electrodes 1, 2 and to be worn on the head 
4 during mitigation of abnormal brain activity, and, more 
particularly, to facilitate non-invasive neuromodulation sig 
nal delivery to a subjects brain. 
0058 EEG from a subject may be collected through the 
EEG acquisition circuit 108, which may include any form of 
EEG amplifier instrument known in the art, through an EEG 
interface 111 that may include connectors 105. At least one 
additional electrode 16 may be carried by the cap 3 and 
positioned to sense and transmit EEG signals to the EEG 
acquisition circuit 108. Alternatively, a stimulating electrode 
1 may also serve as an EEG sensor. In other words, one or 
more stimulating electrodes 1 may be coupled to the EEG 
acquisition circuit 108 and configured to sense and transmit 
EEG signals to the EEG acquisition circuit 108. The cap 3 
may also carry electrical conductors 5 that provide signal 
paths between an electrical stimulation signal source Such as 
the signal generator circuit 107 of the diagnostic and treat 
ment apparatus 100 and stimulating electrodes 1 and ground 
electrodes 2; and the electrical conductors 5 may also provide 
signal paths between an EEG acquisition circuit 108 and 
additional electrodes 16, whereby the conductors may elec 
trically couple to connectors 105 at a stimulation signal inter 
face 110 and an EEG interface 111 of a diagnostic and treat 
ment apparatus 100. The stimulating electrodes 1 and ground 
electrodes 2 may be permanently or removably affixed into 
the cap 3 in cap locations where, when the cap 3 is placed on 
a subjects head 4 in a predetermined orientation, the stimu 
lating electrodes 1 and ground electrodes 2 are positioned 
proximate to respective areas 11 of brain tissues to be stimu 
lated, e.g., areas of brain tissue associated with abnormal 
brain activity. 
0059. The electrodes 1, 2 may be permanently or remov 
ably supported in cap locations on the cap 3 so that, when the 
cap is worn on a subjects head in a predetermined orienta 
tion, a vector path 12 extending between the stimulating 
electrode 1 and the ground electrode 2 passes through the 
desired area 11 of brain tissues to be stimulated. Further, the 
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cap 3 may be sized in various ways to fit or to be adjustable to 
a variety of sizes and shapes of human heads 4 and to carry 
any number of stimulating electrodes 1 and ground electrodes 
2 in cap locations that will cause neuromodulation signals to 
pass along vector paths 12 through predetermined locations 
of abnormal brain activity 11 in a subject’s brain 10. The 
electrodes 1, 2 may Subsequently be removed and placed in 
new cap locations that will cause neuromodulation signals to 
pass along vector paths 12 through predetermined locations 
of abnormal brain activity 11 in a second subject’s brain 10. 
0060. The cap 3 may be configured to carry any number of 
electrical circuits known in the art for storing information. As 
shown in FIG. 5, such circuit may include a radio frequency 
identification (RFID) chip 7 incorporated into a cap 3 and 
utilized to store information including, but not limited to, the 
identification of the subject the cap is intended to be used on, 
dates and times of use, parameters of an electrical stimulation 
signal to be used in association with the cap and delivery of 
non-invasive neuromodulation, a total number of times the 
cap has been used and monitoring data associated with qual 
ity of use. 
0061 The diagnostic and treatment apparatus 100 may 
include any number of external devices that may be utilized in 
the process of providing assessment, diagnostics, or therapy 
and that may be coupled to the device interface circuit 109 and 
interfaced through a device interface 113 that may include 
connectors 105. For example, the apparatus 100 may include 
an RFID reader 14 for establishing electrical connectivity 
between the microcontroller 106 and the RFID chip 7through 
a device interface 113. The use of an RFID reader 14 and 
RFID chip 7 creates a radio frequency pathway 13 that allows 
information incorporated into the RFID chip 7 may be 
accessed and utilized by software executed by the microcon 
troller 106 and/or an interfaced computer 101. 
0062. As shown in the embodiment illustrated in FIG. 6, as 
an alternative to the use of an RFID chip 7, other suitable 
methods known in the art for accessing information stored in 
electrical circuits may be used, such as methods that use 
direct electrical connections via conductors such as wires 8. 
Such methods may include the use of any number of program 
mable memory circuits 9 connected via wires 8 to a memory 
circuit programmer 15, which may be further interfaced to the 
microcontroller 106 and/or the computer 101 through the 
device interface 113, such that information incorporated into 
the programmable memory circuit 9 may be accessed and 
utilized by the microcontroller 106 and/or the computer 101 
via, for example, software executed by the computer 101. 
0063 Alternatively, neuromodulation may be used as a 
method of treatment for fibromyalgia in combination with 
treatment of other coexisting physical conditions that may or 
may not be associated with fibromyalgia. In addition, or alter 
natively, neuromodulation may be used as a method of treat 
ment in combination with otherforms of treatment utilized to 
affect symptoms of fibromyalgia. 
What is claimed is: 
1. A method for treating brain-related chronic pain disor 
ders, the method including the steps of 
assessing the brain function of a Subject Suffering from 
chronic pain; 
determining a pain-related abnormal brain condition by 
determining the presence of brain dysfunction related to 
pain; 
locating at least one area of abnormal brain activity asso 
ciated with the brain dysfunction; and 
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mitigating the brain dysfunction by applying an electrical 
stimulation signal to tissues corresponding to the at least 
one area of abnormal brain activity. 
2. The method of claim 1 in which the electrical stimulation 
signal comprises waveforms configured to minimize tissue 
impedance. 
3. The method of claim 2 in which the electrical stimulation 
signal comprises an AMPWM signal. 
4. The method of claim 1 in which: 
at least one of the assessing and locating steps includes 
obtaining an electroencephalogram (EEG) of the Sub 
ject's electrical brain activity; 
the determining step includes obtaining a quantitative 
assessment (qEEG) of the subject's EEG and making a 
statistical comparison between the subject’s qEEG and a 
database of qEEGs of either healthy normal individuals 
brain functions or the brain functions of individuals 
suffering from the chronic pain-related abnormal brain 
function condition; and 
the mitigating step includes generating and applying to the 
Subject an electrical stimulation signal having at least 
one parameter configured to modulate at least one 
abnormal aspect of the subject's EEG, which corre 
sponds to at least one statistically significant difference 
found in the statistical comparison of qEEGs. 
5. The method of claim 4 in which the mitigating step 
includes testing for EEG lead interface integrity by analyzing 
a measured EEG signal. 
6. The method of claim 1 in which: 
the determining step includes diagnosing fibromyalgia by 
making a statistical comparison between the Subjects 
qEEG and a database of qBEGs of either normal, healthy 
individuals or individuals suffering from fibromyalgia, 
and 
the mitigating step includes generating and applying to the 
Subject a neuromodulation signal. 
7. The method of claim 6 in which at least one neuromodu 
lation signal parameter to be configured for modulation is 
selected from the group of parameters consisting of carrier 
signal frequency, neuromodulation signal frequency, ampli 
tude, waveform, duty cycle, application times, and phase. 
8. The method of claim 6 in which the neuromodulation 
signal is applied using an apparatus comprising: 
a signal generation and interface module including a 
microcontroller configured to generate signal wave 
forms and coupled to a signal generator circuit config 
ured to transform the signal waveforms into desired 
AMPWM neuromodulation signals; 
a cap configured to be worn on a Subjects head and carry 
ing first and second electrodes in respective cap loca 
tions that, when the cap is placed on a Subjects head, 
position the electrodes adjacent a predetermined area of 
brain tissues to be stimulated; and 
electrical conductors that provide signal paths between the 
signal generation and interface module and the cap. 
9. The method of claim 6 in which: 
EEG data is collected during neuromodulation signal 
application; 
at least one statistic associated with the collected EEG data 
is determined by analyzing the collected EEG data using 
at least one real-time computational algorithm; and 
at least one electrical stimulation signal parameter is modi 
fied in response to the at least one statistic. 
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10. The method of claim 6 in which the neuromodulation 
signal is applied repeatedly, alternating with rest periods. 
11. The method of claim 6 in which: 
at least one of the assessing and locating steps includes 
obtaining an electroencephalogram (EEG) of the Sub 
ject's electrical brain activity; 
the diagnosing step includes obtaining a quantitative 
assessment (qEEG) of the subject's EEG and making a 
statistical comparison between the subject’s qEEG and a 
database of qEEGs of either healthy normal individuals 
brain functions or the brain functions of individuals 
suffering from the chronic pain-related abnormal brain 
function condition; and 
the mitigating step includes generating and applying to the 
Subject a neuromodulation signal having at least one 
parameter configured to modulate at least one abnormal 
aspect of the subjects EEG, which corresponds to at 
least one statistically significant difference found in the 
statistical comparison of qEEGs: 
the assessing and quantitative assessment steps are 
repeated at least once; and 
the neuromodulation signal parameters are modified in 
accordance with the findings of the repeated quantitative 
assessment step. 
12. The method of claim 10 in which repeated applications 
of neuromodulation signals are continued until the Subjects 
abnormal brain function has been modulated. 
13. The method of claim 10 in which repeated applications 
of neuromodulation signals are continued until the subjects 
symptoms have been mitigated. 
14. The method of claim 1 in which at least one of the 
assessing and locating steps includes: 
collecting EEG, MRI, PET, or SPECT data during electri 
cal stimulation signal application; 
determining at least one statistic associated with the col 
lected EEG, MRI, PET, or SPECT data by analyzing the 
collected data using at least one real-time computational 
algorithm; and 
modifying at least one electrical stimulation signal param 
eter in response to the at least one statistic. 
15. The method of claim 1 in which: 
the diagnosing step includes obtaining a quantitative 
assessment of the Subject's brain function; and 
identifying any abnormal brain activity by making a statis 
tical comparison between the Subject’s quantitative 
brain function assessment and a database of quantitative 
assessments of either healthy normal individuals’ brain 
functions or the brain functions of individuals suffering 
from the chronic pain-related abnormal brain function 
condition. 
16. The method of claim 1 in which the mitigating step 
includes mitigating abnormal brain activity by applying a 
neuromodulation signal to tissues corresponding to the at 
least one area of abnormal brain activity. 
17. The method of claim 16 in which the mitigating step 
includes: 
applying a neuromodulation signal along a signal path 
between an electrical stimulation signal source and a 
stimulating electrode; and 
positioning the stimulating electrode proximate brain tis 
Sues in the at least one area of abnormal brain activity. 
18. The method of claim 16 in which the mitigating step 
includes: 
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applying a neuromodulation signal along a signal path 
between an electrical stimulation signal source and a 
stimulating electrode; and 
positioning the stimulating electrode on the Subject's scalp 
proximate brain tissues in the at least one area of abnor 
mal brain activity. 
19. The method of claim 18 in which the mitigating step 
includes positioning a ground electrode such that a vector 
path between the stimulating electrode and the ground elec 
trode passes proximate tissues in the at least one area of 
abnormal brain activity. 
20. The method of claim 18 in which the mitigating step 
includes positioning a ground electrode such that a vector 
path between the stimulating electrode and the ground elec 
trode passes through tissues in the at least one area of abnor 
mal brain activity. 
21. The method of claim 10 in which the step of applying 
the electrical stimulation signal repeatedly alternating with 
rest periods includes: 
repeating the assessing and quantitative assessment steps at 
least once following electrical stimulation signal appli 
cation; and 
reapplying the electrical stimulation signals with signal 
parameters modified in accordance with the findings of 
the repeated qualitative assessment step. 
k k k k k 
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